Comparison of Apnea Tolerance in Two Positions of Patients With BMI 30-40
|ClinicalTrials.gov Identifier: NCT03056820|
Recruitment Status : Completed
First Posted : February 17, 2017
Last Update Posted : February 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|General Surgery||Other: 25° head-up position Other: 55° head-up position||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||74 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||The person measuring and recording the study data will be blinded.|
|Primary Purpose:||Health Services Research|
|Official Title:||Comparison of Apnea Tolerance in Two Positions of Patients With Body Mass Index (BMI) 30-40|
|Actual Study Start Date :||May 2010|
|Actual Primary Completion Date :||March 2011|
|Actual Study Completion Date :||March 2011|
Active Comparator: A - 25° head-up position
Participants will be positioned at 25° angle for procedure.
Other: 25° head-up position
Participant will be positioned at 25° angle for procedure.
Active Comparator: B - 55° head-up position
Participants will be positioned at 55° angle for procedure.
Other: 55° head-up position
Participant will be positioned at 55° angle for procedure.
- Tolerable Apnea Time (TAT) [ Time Frame: Time between start of induction of general anesthesia (SpO2 100%) to decline of SpO2 94%, up to eight minutes ]Measure of the TAT between groups to determine if the TAT is a function of the participant's position.
- Length of time to intubation (TTI) [ Time Frame: Time between start of the tracheal intubation procedure to completion of tracheal intubation, up to 2 minutes ]
- Peripheral arterial hemoglobin oxygen saturation (SpO2) trough [ Time Frame: Time until SpO2 decreased to 92%, up to 8 minutes ]Measure of the rebound SpO2. It is the lowest SpO2 reading reached subsequent to start of mechanical ventilation at the SpO2 value of 94% and it represents final completion of SpO2 decline.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03056820
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|Principal Investigator:||Mirsad Dupanović, MD||University of Kansas Medical Center|